|
1
|
Bernick PE, Klimstra DS, Shia J, Minsky B,
Saltz L, Shi W, Thaler H, Guillem J, Paty P, Cohen AM and Wong WD:
Neuroendocrine carcinomas of the colon and rectum. Dis Colon
Rectum. 47:163–169. 2004.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Staren ED, Gould VE, Jansson DS, Hyser M,
Gooch GT and Economou SG: Neuroendocrine differentiation in ‘poorly
differentiated’ colon carcinomas. Am Surg. 56:412–419.
1990.PubMed/NCBI
|
|
3
|
Rindi G, Mete O, Uccella S, Basturk O, La
Rosa S, Brosens LAA, Ezzat S, de Herder WW, Klimstra DS, Papotti M,
et al: Overview of the 2022 WHO classification of neuroendocrine
neoplasms. Endocr Pathol. 33:115–154. 2022.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Ahadi M, Sokolova A, Brown I, Chou A and
Gill AJ: The 2019 World Health Organization Classification of
appendiceal, colorectal and anal canal tumours: An update and
critical assessment. Pathology. 53:454–461. 2021.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Hamilton SR, Bosman FT, Boffetta P, Ilyas
M, Morreau H, Nakamura SI, Quirke P, Riboli E and Sobin LH:
Carcinoma of the colon and rectum. In: WHO Classification of
Tumours of the Digestive System. 4th ed edition. Bosman FT,
Carneiro F, Hruban RH and Theise ND (eds). IARC Press, Lyon,
pp134-146, 2010.
|
|
6
|
Takeuchi K, Kuwano H, Tsuzuki Y, Ando T,
Sekihara M, Hara T and Asao T: Clinicopathological characteristics
of poorly differentiated adenocarcinoma of the colon and rectum.
Hepatogastroenterology. 51:1698–1702. 2004.PubMed/NCBI
|
|
7
|
Kazama Y, Watanabe T, Kanazawa T, Tanaka
J, Tanaka T and Nagawa H: Poorly differentiated colorectal
adenocarcinomas show higher rates of microsatellite instability and
promoter methylation of p16 and hMLH1: A study matched for T
classification and tumor location. J Surg Oncol. 97:278–283.
2008.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Yazawa K, Nakamura F, Masukawa D, Sato S,
Hiroshima Y, Yabushita Y, Mori R, Matsuyama R, Kato I, Taniguchi H,
et al: Low incidence of high-grade pancreatic intraepithelial
neoplasia lesions in a crmp4 gene-deficient mouse model of
pancreatic cancer. Transl Oncol. 13(100746)2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
WHO Classification of Tumours Editorial
Board. Digestive system tumours: WHO classification of tumours, 5th
edition, volume 1. World Health Organization, International Agency
for Research on Cancer, Lyon, 2019.
|
|
10
|
Multi-institutional registry of large
bowel cancer in Japan, Japanese Society for Cancer of the Colon and
Rectum, 1992-2015. https://ndlsearch.ndl.go.jp/books/R100000002-I000000155666.
|
|
11
|
Ueno H, Konishi T, Ishikawa Y, Shimazaki
H, Ueno M, Aosasa S, Saiura A, Hase K and Yamamoto J: Prognostic
value of poorly differentiated clusters in the primary tumor in
patients undergoing hepatectomy for colorectal liver metastasis.
Surgery. 157:899–908. 2015.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Bosman FT, Carneiro F, Hruban RH and
Theise ND (eds): WHO Classification of tumours of the digestive
system: WHO classification of tumours, 4th edition, volume 3. World
Health Organization, International Agency for Research on Cancer,
Lyon, 2010.
|
|
13
|
Rindi G, Petrone G and Inzani F: The 2010
WHO classification of digestive neuroendocrine neoplasms: A
critical appraisal four years after its introduction. Endocr
Pathol. 25:186–192. 2014.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Inzani F, Petrone G and Rindi G: The New
World Health Organization Classification for pancreatic
neuroendocrine neoplasia. Endocrinol Metab Clin North Am.
47:463–470. 2018.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Assarzadegan N and Montgomery E: What is
new in the 2019 World Health Organization (WHO) classification of
tumors of the digestive system: Review of selected updates on
neuroendocrine neoplasms, appendiceal tumors, and molecular
testing. Arch Pathol Lab Med. 145:664–677. 2021.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Dasari A, Mehta K, Byers LA, Sorbye H and
Yao JC: Comparative study of lung and extrapulmonary poorly
differentiated neuroendocrine carcinomas: A SEER database analysis
of 162,983 cases. Cancer. 124:807–815. 2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Klimstra DS, Beltran H, Lilenbaum R and
Bergsland E: The spectrum of neuroendocrine tumors: Histologic
classification, unique features and areas of overlap. Am Soc Clin
Oncol Educ Book. 92–103. 2015.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Scott N, West NP, Cairns A and Rotimi O:
Is medullary carcinoma of the colon underdiagnosed? An audit of
poorly differentiated colorectal carcinomas in a large national
health service teaching hospital. Histopathology. 78:963–969.
2021.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Marchevsky AM and Wick MR: Diagnostic
difficulties with the diagnosis of small cell carcinoma of the
lung. Semin Diagn Pathol. 32:480–488. 2015.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Sorbye H, Welin S, Langer SW, Vestermark
LW, Holt N, Osterlund P, Dueland S, Hofsli E, Guren MG, Ohrling K,
et al: Predictive and prognostic factors for treatment and survival
in 305 patients with advanced gastrointestinal neuroendocrine
carcinoma (WHO G3): The NORDIC NEC study. Ann Oncol. 24:152–160.
2013.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Fluge Ø, Gravdal K, Carlsen E, Vonen B,
Kjellevold K, Refsum S, Lilleng R, Eide TJ, Halvorsen TB, Tveit KM,
et al: Expression of EZH2 and Ki-67 in colorectal cancer and
associations with treatment response and prognosis. Br J Cancer.
101:1282–1289. 2009.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Tong G, Zhang G, Liu J, Zheng Z, Chen Y,
Niu P and Xu X: Cutoff of 25% for Ki67 expression is a good
classification tool for prognosis in colorectal cancer in the
AJCC-8 stratification. Oncol Rep. 43:1187–1198. 2020.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Mori N, Yokota J, Akiyama T, Sameshima Y,
Okamoto A, Mizoguchi H, Toyoshima K, Sugimura T and Terada M:
Variable mutations of the RB gene in small-cell lung carcinoma.
Oncogene. 5:1713–1717. 1990.PubMed/NCBI
|
|
24
|
Febres-Aldana CA, Chang JC, Ptashkin R,
Wang Y, Gedvilaite E, Baine MK, Travis WD, Ventura K, Bodd F, Yu
HA, et al: Rb tumor suppressor in small cell lung cancer: Combined
genomic and IHC analysis with a description of a distinct
Rb-proficient subset. Clin Cancer Res. 28:4702–4713.
2022.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Angerilli V, Sabella G, Simbolo M, Lagano
V, Centonze G, Gentili M, Mangogna A, Coppa J, Munari G, Businello
G, et al: Comprehensive genomic and transcriptomic characterization
of high-grade gastro-entero-pancreatic neoplasms. Br J Cancer.
131:159–170. 2024.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Yachida S, Vakiani E, White CM, Zhong Y,
Saunders T, Morgan R, de Wilde RF, Maitra A, Hicks J, Demarzo AM,
et al: Small cell and large cell neuroendocrine carcinomas of the
pancreas are genetically similar and distinct from
well-differentiated pancreatic neuroendocrine tumors. Am J Surg
Pathol. 36:173–184. 2012.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Hijioka S, Hosoda W, Matsuo K, Ueno M,
Furukawa M, Yoshitomi H, Kobayashi N, Ikeda M, Ito T, Nakamori S,
et al: Rb loss and KRAS mutation are predictors of the response to
platinum-based chemotherapy in pancreatic neuroendocrine neoplasm
with grade 3: A Japanese multicenter pancreatic NEN-G3 study. Clin
Cancer Res. 23:4625–4632. 2017.PubMed/NCBI View Article : Google Scholar
|
|
28
|
AACR Project GENIE Consortium. AACR
project GENIE: Powering precision medicine through an international
consortium. Cancer Discov. 7:818–831. 2017.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Shia J, Tang LH, Weiser MR, Brenner B,
Adsay NV, Stelow EB, Saltz LB, Qin J, Landmann R, Leonard GD, et
al: Is nonsmall cell type high-grade neuroendocrine carcinoma of
the tubular gastrointestinal tract a distinct disease entity? Am J
Surg Pathol. 32:719–731. 2008.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Ogimi T, Sadahiro S, Kamei Y, Chan LF,
Miyakita H, Saito G, Okada K, Suzuki T and Kajiwara H: Distribution
of Neuroendocrine marker-positive cells in colorectal cancer tissue
and normal mucosal tissue: Consideration of histogenesis of
neuroendocrine cancer. Oncology. 97:294–300. 2019.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Iijima M, Yokobori T, Mogi A, Shimizu K,
Yajima T, Kosaka T, Ohtaki Y, Obayashi K, Nakazawa S, Gombodorj N,
et al: Genetic and immunohistochemical studies investigating the
histogenesis of neuroendocrine and carcinomatous components of
combined neuroendocrine carcinoma. Ann Surg Oncol. 26:1744–1750.
2019.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Cho YB, Yang SS, Lee WY, Song SY, Kim SH,
Shin HJ, Yun SH and Chun HK: The clinical significance of
neuroendocrine differentiation in T3-T4 node-negative colorectal
cancer. Int J Surg Pathol. 18:201–206. 2010.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Grabowski P, Schönfelder J, Ahnert-Hilger
G, Foss HD, Heine B, Schindler I, Stein H, Berger G, Zeitz M and
Scherubl H: Expression of neuroendocrine markers: A signature of
human undifferentiated carcinoma of the colon and rectum. Virchows
Arch. 441:256–263. 2002.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Conteduca V, Oromendia C, Eng KW, Bareja
R, Sigouros M, Molina A, Faltas BM, Sboner A, Mosquera JM, Elemento
O, et al: Clinical features of neuroendocrine prostate cancer. Eur
J Cancer. 121:7–18. 2019.PubMed/NCBI View Article : Google Scholar
|
